title: Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.
abstract: BACKGROUND
  Non-occupational HIV post-exposure prophylaxis (NPEP) is prescribed following a risk exposure in an effort to reduce the risk of HIV seroconversion. We aimed to describe the prescribing practices of NPEP at RPA Sexual Health in Sydney, the prevalence and correlates of adverse events (AEs), and factors associated with completing the 28-day course.
  
  
  METHODS
  The study population included individuals prescribed NPEP during January 2008-December 2011. Correlates of AEs and course completion were assessed by logistic regression.
  
  
  RESULTS
  On 319 occasions during the study period, 282 individuals presented for NPEP. Over 90% of presentations followed unprotected anal intercourse between men, mostly receptive (63.6%). Tenofovir-emtricitabine-stavudine (n=149; 46.7%) and tenofovir-emtricitabine (n=136; 42.6%) were most commonly prescribed. AEs were reported at 101 presentations (31.7%, 95% confidence interval (CI): 26.6-37.1%), with nausea and lethargy/malaise being the most common. Younger age (P for trend=0.032), earlier year of NPEP prescription (P for trend=0.011), being prescribed a regimen other than tenofovir-emtricitabine (P=0.026), changing the NPEP regimen (P<0.001) and known completion of the course (P=0.005) were independently associated with AEs. The course was completed in 228 presentations (71.5%, 95% CI: 66.2-76.4%). Completion was associated with reporting AEs (P=0.007) and changing regimen (P=0.001). No documented NPEP failures were identified, although two recipients subsequently seroconverted to HIV due to ongoing high-risk behaviour.
  
  
  CONCLUSIONS
  NPEP is appropriately targeted to the highest risk HIV exposures at our clinic. Active recall may improve follow-up rates in NPEP recipients.
authors: RPA Sexual Health, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
authors: Trine
authors: T
authors: Gulholm
authors: Salina
authors: S
authors: Jamani
authors: I Mary
authors: IM
authors: Poynten
authors: David J
authors: DJ
authors: Templeton
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001315:Australia; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D015658:HIV Infections / Q000517:prevention & control*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage; D056990:Post-Exposure Prophylaxis / Q000706:statistics & numerical data*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012309:Risk-Taking; D018119:Stavudine / Q000008:administration & dosage; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D018119:Stavudine; D000068679:Emtricitabine; D000225:Adenine